EMA fol­lows FDA to ap­prove Roche's Tecen­triq com­bo for front­line use in triple neg­a­tive breast can­cer

Months af­ter Roche se­cured US ap­proval for its check­point in­hibitor Tecen­triq, in com­bi­na­tion with Cel­gene’s Abrax­ane, for front­line use in an ag­gres­sive, tough-to-treat sub­group of breast can­cer pa­tients — the EU has fol­lowed suit.

On Thurs­day, the Swiss gi­ant said the Tecen­triq com­bo is the first can­cer im­munother­a­py reg­i­men to be cleared by Eu­ro­pean reg­u­la­tors for triple-neg­a­tive breast can­cer (TNBC).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER